NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Leukemia

• Publication date

  2013-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2012.357PMID 23295735
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  2013cited by this paper
• NOTCH1 mutations in CLL associated with trisomy 12.

  2012cited by this paper
• Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34

  2012cited by this paper
• Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations

  2012cited by this paper
• Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome

  2012cited by this paper
• Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

  2012cited by this paper
• Rearrangement of NOTCH1 or BCL3 can independently trigger progression of CLL.

  2012cited by this paper
• NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL

  2012cited by this paper
• Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns.

  2012cited by this paper
• Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

  2011cited by this paper
• Oncogenic and tumor suppressor functions of Notch in cancer: it’s NOTCH what you think

  2011cited by this paper
• Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

  2011cited by this paper
• Chronic lymphocytic leukemia

  2011cited by this paper
• Notch signalling in T‐cell lymphoblastic leukaemia/lymphoma and other haematological malignancies

  2011cited by this paper
• Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation

  2011cited by this paper
• The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia.

  2010cited by this paper
• From pathogenesis to treatment of chronic lymphocytic leukaemia

  2010cited by this paper
• Therapeutic antibody targeting of individual Notch receptors

  2010cited by this paper
• NF-κB as a therapeutic target in chronic lymphocytic leukemia

  2010cited by this paper
• Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design

  2010cited by this paper
• Chemoimmunotherapy in chronic lymphocytic leukemia.

  2010cited by this paper
• Chemoimmunotherapy of chronic lymphocytic leukemia

  2010cited by this paper
• NOTCH1 PEST domain mutation is an adverse prognostic factor in B‐CLL

  2010cited by this paper
• Richter syndrome: molecular insights and clinical perspectives

  2009cited by this paper
• A new genetic lesion in B‐CLL: a NOTCH1 PEST domain mutation

  2009cited by this paper
• Gamma-secretase inhibitors reverse glucocorticoid resistance in T-ALL

  2008cited by this paper
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

  2008cited by this paper
• The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.

  2008cited by this paper
• Oncogenic NOTCH1 Control of MYC and PI3K: Challenges and Opportunities for Anti-NOTCH1 Therapy in T-Cell Acute Lymphoblastic Leukemias and Lymphomas

  2008cited by this paper
• Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication

  2008cited by this paper
• International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia

  2007cited by this paper
• ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia

  2007cited by this paper
• Richter syndrome

  2005cited by this paper
• Regression models for relative survival

  2004cited by this paper
• Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936

  2003cited by this paper
• Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia

  2002cited by this paper
• Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome).

  2002cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• The relative survival rate: a statistical methodology.

  1961cited by this paper

• The biology and evolution of Richter transformation in chronic lymphocytic leukemia.

  2026cites this paper
• Prognostic and predictive impact of NOTCH1 mutations in patients with chronic lymphocytic leukemia: a tertiary single-center experience

  2026cites this paper
• Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes

  2025cites this paper
• Genetic Profiling of Acute and Chronic Leukemia via Next-Generation Sequencing: Current Insights and Future Perspectives

  2025cites this paper
• Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis

  2025cites this paper
• Updates on the Treatment of Richter’s Syndrome, Including Novel Combination Approaches

  2025cites this paper
• Prognostic factors in chronic lymphocytic leukaemia – the old, the new and the future

  2025cites this paper
• Analysis and Interpretation of Somatic NMD-Escaping Variants in Oncogenes and Dual-Function Genes across Adult and Pediatric Cancer Cohorts

  2025cites this paper
• Clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy in patients with chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular Therapy.

  2025cites this paper
• Molecular Features Accompanying Richter’s Transformation in Patients with Chronic Lymphocytic Leukemia

  2025cites this paper
• Prognostic and predictive impact of NOTCH1 mutation in chronic lymphocytic leukemia: a systematic review

  2024cites this paper
• Analysis of Primary Chronic Lymphocytic Leukemia Cells’ Signaling Pathways

  2024cites this paper
• The molecular map of CLL and Richter's syndrome.

  2024cites this paper
• Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma

  2024cites this paper
• Multiple omics levels of chronic lymphocytic leukemia

  2024cites this paper
• Prognostication in chronic lymphocytic leukemia.

  2024cites this paper
• Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies

  2024cites this paper
• From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia.

  2023cites this paper
• Practical Management of Richter Transformation in 2023 and Beyond.

  2023cites this paper
• An Aggressive Course of Transformed Splenic Diffuse Red Pulp Small B-Cell Lymphoma With Novel Somatic Loss-of-Function Mutation in RB1

  2023cites this paper
• Cytogenetics in the management of chronic lymphocytic leukemia: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).

  2023cites this paper
• SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia

  2023cites this paper
• Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond

  2022cites this paper
• Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group.

  2022cites this paper
• Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

  2022cites this paper
• Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

  2022cites this paper
• Emerging Therapies for the Management of Richter Transformation.

  2022cites this paper
• Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia.

  2022cites this paper
• Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1

  2022cites this paper
• Biology and Treatment of Richter Transformation

  2022cites this paper
• Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape

  2022cites this paper
• The role of SF3B1 and NOTCH1 in the pathogenesis of leukemia

  2022cites this paper
• Deleterious mutations in esophageal carcinoma cuniculatum detected by next generation sequencing.

  2022cites this paper
• A clinical case of the effective combined use of BCL-2 and PI3K inhibitors in the treatment of a patient with an unfavorable chronic lymphocytic leukemia with transformation into diffuse large B-cell lymphoma (Richter’s syndrome)

  2022cites this paper
• Notch receptors in GtoPdb v.2021.2

  2021cites this paper
• The Predominant Prognostic Significance of NOTCH1 Mutation Defined by Emulsion PCR in Chronic Lymphocytic Leukemia

  2021cites this paper
• Analyzing The Mutations Of Notch1 And Sf3b1 Genes In Cases With CLL Detected Isolated 13q Deletion

  2021cites this paper
• Richter Syndrome

  2021cites this paper
• NOTCH1 drives immune-escape mechanisms in B cell malignancies

  2021cites this paper
• Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets

  2021cites this paper
• From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct

  2021cites this paper
• Precision Diagnostics in Lymphomas - Recent Developments and Future Directions.

  2021cites this paper
• Driving out chronic lymphocytic leukemia with CAR T-cells.

  2021cites this paper
• Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.

  2021cites this paper
• From Descriptive to Functional Genomics of Leukemias Focusing on Genome Engineering Techniques

  2021cites this paper
• The Effect of Blood Lactate Level on Prognosis in Patients with Hemorrhagic and Ischemic Cerebrovascular Disease

  2021cites this paper
• Genetics and Diagnostic Approach to Lymphoblastic Leukemia/Lymphoma.

  2021cites this paper
• Role of Notch Receptors in Hematologic Malignancies

  2020cites this paper
• Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia.

  2020cites this paper
• Clinical Value of NOTCH1 Mutations Detection among Chronic Lymphocytic Leukemia Patients

  2020cites this paper
• Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukemia

  2020cites this paper
• Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies

  2020cites this paper
• Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2020cites this paper
• PET/CT在Richter综合征中的诊断价值

  2020cites this paper
• Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

  2020cites this paper
• Genetics of “high-risk” chronic lymphocytic leukemia in the times of chemoimmunotherapy

  2020cites this paper
• The N-acetylgalactosamine-transferase11 (GALNT11) activation in leukemia and the role of cyclophosphamide and cytarabine in expression of this enzyme

  2019cites this paper
• Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia

  2019cites this paper
• Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells

  2019cites this paper
• Immunohistochemical Expression of CD27 in Bone Marrow Biopsies of Chronic Lymphocytic Leukemia Patients

  2019cites this paper
• The frequency of NOTCH1 variants in T-acute lymphoblastic leukemia/lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma among Jordanian patients.

  2019cites this paper
• Targeted therapies in CLL. New drugs against CLL recurrent mutations

  2019cites this paper
• Laboratory Diagnosis of Chronic Lymphocytic Leukaemia

  2019cites this paper
• Chronic lymphocytic leukaemia: from genetics to treatment

  2019cites this paper
• Prognostic Markers

  2019cites this paper
• [Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition):lymphoid tumors].

  2019cites this paper
• Hodgkin lymphoma transformation of chronic lymphocytic leukemia—A real life data from the Polish Lymphoma Research Group

  2019cites this paper
• Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment

  2019cites this paper
• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

  2019cites this paper
• Overview of non‐coding mutations in chronic lymphocytic leukemia

  2019cites this paper
• Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty

  2019cites this paper
• Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.

  2019cites this paper
• Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.

  2018cites this paper
• Biology and treatment of Richter syndrome.

  2018cites this paper
• The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies

  2018cites this paper
• NOTCH1 Aberrations in Chronic Lymphocytic Leukemia

  2018cites this paper
• NOTCH1突变与慢性淋巴细胞白血病Richter转化的关系研究进展

  2018cites this paper
• Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review

  2018cites this paper
• Phenotypic Characterization of Trisomy 12 Monoclonal B‐Cell Lymphocytosis

  2018cites this paper
• Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL

  2018cites this paper
• The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia

  2018cites this paper
• Characterization of Chronic Lymphocytic Leukemia by aCGH/MLPA

  2018cites this paper
• Small B cells in the bone marrow associated with diffuse large B-cell lymphoma and cold agglutinin disease

  2018cites this paper
• Bepridil exhibits anti‐leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia

  2018cites this paper
• Genomic Biomarkers in Pathogenesis and Clinical Care of Chronic Lymphocytic Leukemia

  2018cites this paper
• Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia

  2018cites this paper
• Studies of Bruton’s tyrosine kinase inhibitors in B-cell malignancies

  2018cites this paper
• Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma

  2017cites this paper
• Notch Signaling

  2017cites this paper
• Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22

  2017cites this paper
• Innovative targeted therapies for chemorefractory B-cell non-Hodgkin lymphomas

  2017cites this paper
• Prognostic markers and DNA methylation profiling in lymphoid malignancies

  2017cites this paper
• Lymphoma classification update: B-cell non-Hodgkin lymphomas

  2017cites this paper
• Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

  2017cites this paper
• 2016 WHO Classification update—What's new in lymphoid neoplasms

  2017cites this paper
• Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia

  2017cites this paper
• MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia

  2017cites this paper
• New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia

  2017cites this paper
• Diferenciación plasmocelular en linfomas no-Hodgkin de células B: implicaciones clínicas y terapéuticas

  2017cites this paper
• Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients

  2017cites this paper